Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (Q33739253)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

6

object named as

Hope S Rugo

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

5

object named as

Beverly Moy

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

11

object named as

Nancy U Lin

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

object named as

Melissa E Hughes

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Ines Vaz-Luis

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Rebecca A Ottesen

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

P Kelly Marcom

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Richard L Theriault

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

John Wilson

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Joyce C Niland

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jane C Weeks

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

R129

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Deconstructing the molecular portraits of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Metastatic behavior of breast cancer subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Genes that mediate breast cancer metastasis to the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Gene-expression signatures in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Identification of brain- and bone-specific breast cancer metastasis genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Subtypes of breast cancer show preferential site of relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

The molecular portraits of breast tumors are conserved across microarray platforms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Genes associated with breast cancer metastatic to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Genes that mediate breast cancer metastasis to lung

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

A multigenic program mediating breast cancer metastasis to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Annual hazard rates of recurrence for breast cancer after primary therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053106

21 June 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR3324

21 January 2018

Estrogen receptors and distinct patterns of breast cancer relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/23025714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes assessment in the NCCN

1 reference

https://pubmed.ncbi.nlm.nih.gov/23025714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23025714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23025714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23025714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status

1 reference

https://pubmed.ncbi.nlm.nih.gov/23025714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR3324

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

release_mapflee2jvb25ia6xbvsquafmm

1 reference

https://api.fatcat.wiki/v0/release/mapflee2jvb25ia6xbvsquafmm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33739253&oldid=2195716238"